The effect of intrauterine infusions of prostaglandin E2 on luteal function in nonpregnant gilts.
Two trials were conducted to study the effects of intrauterine infusions of prostaglandin E2 (PGE2) on luteal function in nonpregnant gilts. Cannulae were surgically implanted on day 9 postestrus into the lumen of each horn with a cephalic vein cannula inserted for collection of peripheral blood. Intrauterine infusions of 0, 25, 75 or 200 microg of PGE2 were initiated at 0900 h on day 12 and administered thereafter every 12 hr until estrus or day 22 in the first trial. The second trial protocol included an increase in the dose of PGE2 administered as well as the frequency of infusion. Infusion of 0, 200, 300 or 400 microg PGE2 was begun at 0300 h on day 12 and continued every 6 hr until estrus or day 22. Cephalic plasma samples for progesterone analysis were collected every six hours from 0300 h on day 11 to 2100 h on day 26 in both trials. In Trial 1 mean plasma progesterone concentrations for all treatments were not different (P>0.05) from the controls on any given day of the estrous cycle. Interestrous interval was unaffected by intrauterine infusion of PGE2. The mean plasma progesterone concentrations for all treatments were not different (P>0.05) from the controls on days 11-18 of the estrous cycle in Trial 2. However, plasma progesterone concentrations for the 200-microg and 300-microg PGE2 groups appeared to be greater than the controls on days 14 and 15, indicating a possible delay in the decline of progesterone for these groups. The mean plasma progesterone concentrations for the treatment groups were lower (P<0.05) than the controls on days 20-26 of the cycle. treatment cycle length did not differ (P>0.05) from previous cycle length; thus treatment with PGE2 had no effect on interestrous interval. PGE2 may have retarded the decline of progesterone secretion by the corpus luteum in some cases, but at these dosages and frequencies of administration PGE2 was ineffective in prolonging luteal maintenance.